We are living in exciting times for urological oncology. The numbers of clinical trials are ever rising, a stream of new substances for tumour therapy is introduced. As it is more challenging than ever to obtain an overview as a clinician, this article aims to summarise the most important news with regard to the 3 most eminent urological tumour entities. Recent data from the most relevant urological and oncological conferences in 2018 on prostate cancer, renal cell carcinoma, and urothelial cancer are reported and their relevance for clinical practice is discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/a-0759-3664 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Pain therapy in urology-overview of current S3 guideline recommendations].
Urologie
May 2024
Klinik für Urologie, Helios Kliniken Schwerin, Wismarsche Straße 393-397, 19055, Schwerin, Deutschland.
Article Synopsis
- * Perioperative pain can negatively impact recovery after surgery, making its management essential for better patient outcomes.
- * The updated guidelines specifically address pain management strategies for both perioperative care and for patients with incurable diseases, particularly in uro-oncology and palliative medicine.
ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma.
Ann Oncol
June 2024
Oncology Institute of Southern Switzerland (EOC-IOSI), Bellinzona; Università della Svizzera italiana (USI), Lugano, Switzerland.
Objective: The objective of this study is to validate the predictive ability of the 2021 European Association of Urology (EAU) risk model compared to that of existing risk models, including the 2019 EAU model and risk scoring tables of the European Organization for Research and Treatment of Cancer, Club Urologico Espanol de Tratamiento Oncologico, and Japanese Nishinihon Uro-oncology Extensive Collaboration Group.
Patients And Methods: This retrospective multi-institutional database study included two cohorts-3024 patients receiving intravesical bacillus Calmette-Guerin (BCG) treatment (BCG cohort) and 789 patients not receiving BCG treatment (non-BCG cohort). The Kaplan-Meier estimate and log-rank test were used to visualize and compare oncological survival outcomes after transurethral surgery among the risk groups.
Assessing the risk to develop a growing teratoma syndrome based on molecular and epigenetic subtyping as well as novel secreted biomarkers.
Cancer Lett
March 2024
Department of Urology, Urological Research Laboratory, Translational UroOncology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany; Lighthouse Project Germ Cell Tumors, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Germany. Electronic address:
In germ cell tumors (GCT), a growing teratoma during chemotherapy with decreasing tumor markers was defined as 'growing teratoma syndrome' (GTS) by Logothetis et al. in 1982. So far, its pathogenesis and specific treatment options remain elusive.
View Article and Find Full Text PDFUpdating germ cell tumour pathogenesis - the ability of seminomas for FOXA2-driven extra-embryonic differentiation.
Histopathology
September 2023
Department of Urology, Urological Research Laboratory, Translational UroOncology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Testicular germ cell tumours are the most common solid malignancies in young men of age 14-44 years. It is generally accepted that both seminomas and non-seminomas arise from a common precursor, the germ cell neoplasia in-situ, which itself is the result of a defective (primordial) germ cell development. The stem cell-like population of the non-seminomas, the embryonal carcinoma, is capable of the differentiation of all three germ layers (teratomas) and extra-embryonic tissues (yolk-sac tumours, choriocarcioma) into cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!